Comparative inhibition of the GH/IGF-I axis obtained with either the targeted secretion inhibitor SXN101959 or the somatostatin analog octreotide in growing male rats

Endocrinology

Volumn 154, Issue 11, 2013, Pages 4237-4248

  Somm, Emmanuel ^a   Bonnet, Nicolas ^a   Zizzari, Philippe ^b   Tolle, Virginie ^b   Toulotte, Audrey ^a   Jones, Richard ^c   Epelbaum, Jacques ^b   Martinez, Alberto ^c   Hüppi, Petra S ^a   Aubert, Michel L ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b INSERM   (France)

^c SYNTAXIN LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GROWTH HORMONE; HORMONE ANTAGONIST; MESSENGER RNA; OCTREOTIDE; SNX 101959; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY GROWTH; BODY HEIGHT; BODY WEIGHT; BONE MASS; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; GENE EXPRESSION; GROWTH HORMONE RELEASE; GROWTH HORMONE SECRETING CELL; HORMONE ACTION; HORMONE SYNTHESIS; HYPOTHALAMUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BONE DEVELOPMENT; BOTULINUM TOXINS; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; MALE; OCTREOTIDE; RATS; RECOMBINANT FUSION PROTEINS;

EID: 84886534177     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1427     Document Type: Article

References (58)

1. Frohman LA, Downs TR, Chomczynski P. Regulation of growth hormone secretion. Front Neuroendocrinol. 1992;13: 344-405.
2. Dieguez C, Casanueva FF. Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. Eur J Endocrinol. 2000;142: 413-417.
3. Melmed S. Medical progress: acromegaly.NEngl J Med. 2006;355: 2558-2573.
4. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119: 3189-3202.
5. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev. 2002;23: 623-646.
6. Sherlock M, Woods C, Sheppard MC. Medical therapy in acromegaly. Nat Rev Endocrinol. 2011;7: 291-300.
7. Giustina A, Chanson P, Bronstein MD, et al.A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95: 3141-3148.
8. Giustina A, Porcelli T. Pituitary gland: medical therapy for acromegaly: can we predict response? Nat Rev Endocrinol. 2009;5: 425-427.
9. Jane JA Jr, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96: 2732-2740.
10. Keith F, John C. Targeted secretion inhibitors-innovative protein therapeutics. Toxins. 2010;2: 2795-2815.
11. Somm E, Bonnet N, Martinez A, et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest. 2012;122: 3295-3306.
12. Sandstedt J, Ohlsson C, Norjavaara E, Nilsson J, Törnell J. Disproportional bone growth and reduced weight gain in gonadectomized male bovine growth hormone transgenic and normal mice. Endocrinology. 1994;135: 2574-2580.
13. Wolf E, Wanke R, Schenck E, Hermanns W, Brem G. Effects of growth hormone overproduction on grip strength of transgenic mice. Eur J Endocrinol. 1995;133: 735-740.
14. Yamashita S, Slanina S, Kado H, Melmed S. Autoregulation of pituitary growth hormone messenger ribonucleic acid levels in rats bearing transplantable mammosomatotrophic pituitary tumors. Endocrinology. 1986;118: 915-918.
15. Leggett J, Harper E, Waite E, Marks P, Martinez A, Lightman S. GHRH receptor-targeted botulinum neurotoxin selectively inhibits pulsatile GH secretion in male rats. Endocrinology. 2013;154(9): 3305-3318.
16. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002;143: 4123-4130.
17. Feelders RA, Hofland LJ, van Aken MO, et al. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Drugs. 2009;69: 2207-2226.
18. Hildebrand T, Rüegsegger P. Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Engin. 1997;1: 15-23.
19. Bikle D, Majumdar S, Laib A, et al. The skeletal structure of insulinlike growth factor I-deficient mice. J Bone Miner Res. 2001;16: 2320-2329.
20. Cannata D, Vijayakumar A, Fierz Y, LeRoith D. The GH/IGF-1 axis in growth and development: new insights derived from animal models. Adv Pediatr. 2010;57: 331-351.
21. LeRoith D. Clinical relevance of systemic and local IGF-I: lessons from animal models. Pediatr Endocrinol Rev. 2008;5(suppl 2): 739-743.
22. Leung KC, Waters MJ, Markus I, Baumbach WR, Ho KK. Insulin and insulin-like growth factor-I acutely inhibit surface translocation of growth hormone receptors in osteoblasts: a novel mechanism of growth hormone receptor regulation. Proc Natl Acad Sci USA. 1997;94: 11381-11386.
23. Madsen K, Friberg U, Roos P, Edén S, Isaksson O. Growth hormone stimulates the proliferation of cultured chondrocytes from rabbit ear and rat rib growth cartilage. Nature. 1983;304: 545-547.
24. Ohlsson C, Mohan S, Sjögren K, et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev. 2009;30: 494-535.
25. Tachas G, Lofthouse S, Wraight CJ, et al. A GH receptor antisense oligonucleotide inhibits hepaticGHreceptor expression, IGF-I production and body weight gain in normal mice. J Endocrinol. 2006; 189: 147-154.
26. Ueland T. Bone metabolism in relation to alterations in systemic growth hormone. Growth Horm IGF Res. 2004;14: 404-417.
27. Wang J, Zhou J, Cheng CM, Kopchick JJ, Bondy CA. Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. J Endocrinol. 2004; 180: 247-255.
28. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003;2: 999-1017.
29. Alba M, Salvatori R. A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated growth hormone deficiency. Endocrinology. 2004;145: 4134-4143.
30. Melmed S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J Clin Invest. 2003;112: 1603-1618.
31. Nagel BH, Palmbach M, Petersen D, Ranke MB. Magnetic resonance images of 91 children with different causes of short stature: pituitary size reflects growth hormone secretion. Eur J pediatr. 1997;156: 758-763.
32. Barinaga M, Bilezikjian LM, Vale WW, Rosenfeld MG, Evans RM. Independent effects of growth hormone releasing factor on growth hormone release and gene transcription. Nature. 1985;314: 279-281.
33. Fukata J, Diamond DJ, Martin JB. Effects of rat growth hormone (rGH)-releasing factor and somatostatin on the release and synthesis of rGH in dispersed pituitary cells. Endocrinology. 1985;117: 457-467.
34. Tanner JW, Davis SK, McArthur NH, French JT, Welsh TH Jr. Modulation of growth hormone (GH) secretion and GH mRNA levels by GH-releasing factor, somatostatin and secretagogues in cultured bovine adenohypophysial cells. J Endocrinol. 1990;125: 109-115.
35. Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21: 123-133.
36. Berelowitz M, Firestone SL, Frohman LA. Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution. Endocrinology. 1981;109: 714-719.
37. BerelowitzM,SzaboM,Frohman LA, Firestone S, Chu L, Hintz RL. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary. Science. 1981; 212: 1279-1281.
38. Szalontay L, Benveniste RJ, Schally AV, et al. Inhibitory effects of GHRH antagonists on human GH-secreting adenoma tissue. Neuroendocrinology. 2012;96: 81-88.
39. Bartlett JM, Charlton HM, Robinson IC, Nieschlag E. Pubertal development and testicular function in the male growth hormonedeficient rat. J Endocrinol. 1990;126: 193-201.
40. Thomas GB, Phelps CJ, Robinson IC. Differential regulation of hypothalamic tuberoinfundibular dopamine neurones in two dwarf rat models with contrasting changes in pituitary prolactin. J Neuroendocrinol. 1999;11: 229-236.
41. Chandrashekar V, Bartke A, Coschigano KT, Kopchick JJ. Pituitary and testicular function in growth hormone receptor gene knockout mice. Endocrinology. 1999;140: 1082-1088.
42. Clemmons DR. Role of insulin-like growth factor-I in diagnosis and management of acromegaly. Endocr Pract. 2004;10: 362-371.
43. Clemmons DR. Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab. 2006;2: 436-446.
44. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone- IGF-I axis. J Clin Invest. 2004;114: 349-356.
45. Ambler GR, Butler AA, Padmanabhan J, Breier BH, Gluckman PD. The effects of octreotide onGHreceptor and IGF-I expression in the GH-deficient rat. J Endocrinol. 1996;149: 223-231.
46. Laursen T, Møller J, Fisker S, Jorgensen JO, Christiansen JS. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)- treated GH-deficient patients. GrowthHormIGF Res. 1999;9: 451-457.
47. Flyvbjerg A, Jørgensen KD, Marshall SM, Orskov H. Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats. Am J Physiol. 1991; 260:E568-E574.
48. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342: 1171-1177.
49. Silva AP, Bethmann K, Raulf F, Schmid HA. Regulation of ghrelin secretion by somatostatin analogs in rats. Eur J Endocrinol. 2005; 152: 887-894.
50. Freda PU, Reyes CM, Conwell IM, Sundeen RE, Wardlaw SL. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy. J Clin Endocrinol Metab. 2003;88: 2037-2044.
51. Gause I, Eden S, Jansson JO, Isaksson O. Effects of in vivo administration of antiserum to rat growth hormone on body growth and insulin responsiveness in adipose tissue. Endocrinology. 1983;112: 1559-1566.
52. Donahue LR, Beamer WG. Growth hormone deficiency in 'little' mice results in aberrant body composition, reduced insulin-like growth factor-I and insulin-like growth factor-binding protein-3 (IGFBP-3), but does not affect IGFBP-2, -1 or -4. J Endocrinol. 1993;136: 91-104.
53. Furuhata Y, Kagaya R, Hirabayashi K, et al. Development of obesity in transgenic rats with low circulating growth hormone levels: involvement of leptin resistance. Eur J Endocrinol. 2000;143: 535-541.
54. Wabitsch M, Heinze E. Body fat in GH-deficient children and the effect of treatment. Horm Res. 1993;40: 5-9.
55. List EO, Berryman DE, Funk K, et al. The Role of GH in adipose tissue: lessons from adipose-specific GH receptor gene-disrupted mice. Mol Endocrinol. 2013;27: 524-535.
56. Bruns C, Dietl MM, Palacios JM, Pless J. Identification and characterization of somatostatin receptors in neonatal rat long bones. Biochem J. 1990;265: 39-44.
57. Mackie EJ, Trechsel U, Bruns C. Somatostatin receptors are restricted to a subpopulation of osteoblast-like cells during endochondral bone formation. Development. 1990;110: 1233-1239.
58. Zapf J, Gosteli-Peter M, Weckbecker G, Hunziker EB, Reinecke M. The somatostatin analog octreotide inhibits GH-stimulated, but not IGF-I-stimulated, bone growth in hypophysectomized rats. Endocrinology. 2002;143: 2944-2952.